Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | UBE2N | P61088 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5364738 | 0.93 | HTR6 (0.79) | HTR6EGFRUBE2NTDP1LMNA | |
| SCHEMBL5356843 | 0.93 | HTR6 (0.70) | HTR6EGFRUBE2NTDP1LMNA | |
| SCHEMBL5357019 | 0.90 | HTR6 (0.64) | HTR6LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL5372213 | 0.87 | HTR6 (0.68) | HTR6LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL5356074 | 0.86 | HTR6 (0.59) | HTR6EGFRUBE2NTDP1LMNA | |
| SCHEMBL5366505 | 0.86 | HTR6 (0.74) | HTR6EGFRUBE2NTDP1LMNA | |
| SCHEMBL5364715 | 0.85 | HTR6 (0.82) | HTR6EGFRUBE2NTDP1LMNA | |
| SCHEMBL5360955 | 0.84 | HTR6 (0.80) | HTR6EGFRUBE2NTDP1LMNA | |
| SCHEMBL5361156 | 0.84 | HTR6 (0.68) | HTR6EGFRUBE2NLMNAHPGD | |
| SCHEMBL5362209 | 0.84 | HTR6 (0.61) | HTR6EGFRMAPTSMN1; SMN2ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | claimed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | claimed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | HTR6, BDKRB1, HTR7 | HTR6 1/4885EGFR 1718/4885UBE2N 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.